- Home
- MIRA vs SONN Comparison
MIRA vs SONN Comparison
Compare MIRA & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- SONN
- Stock Information
- Founded
- MIRA 2020
- SONN N/A
- Country
- MIRA United States
- SONN United States
- Employees
- MIRA N/A
- SONN N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- SONN Health Care
- Exchange
- MIRA Nasdaq
- SONN Nasdaq
- Market Cap
- MIRA 33.7M
- SONN 32.4M
- IPO Year
- MIRA 2023
- SONN N/A
- Fundamental
- Price
- MIRA $1.67
- SONN $5.02
- Analyst Decision
- MIRA
- SONN Strong Buy
- Analyst Count
- MIRA 0
- SONN 1
- Target Price
- MIRA N/A
- SONN $20.00
- AVG Volume (30 Days)
- MIRA 8.9M
- SONN 486.9K
- Earning Date
- MIRA 11-14-2025
- SONN 12-16-2025
- Dividend Yield
- MIRA N/A
- SONN N/A
- EPS Growth
- MIRA N/A
- SONN N/A
- EPS
- MIRA N/A
- SONN N/A
- Revenue
- MIRA N/A
- SONN $1,000,000.00
- Revenue This Year
- MIRA N/A
- SONN $5,376.22
- Revenue Next Year
- MIRA N/A
- SONN N/A
- P/E Ratio
- MIRA N/A
- SONN N/A
- Revenue Growth
- MIRA N/A
- SONN 1689.52
- 52 Week Low
- MIRA $0.73
- SONN $1.08
- 52 Week High
- MIRA $2.45
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- MIRA 60.28
- SONN 53.37
- Support Level
- MIRA $1.57
- SONN $4.42
- Resistance Level
- MIRA $1.80
- SONN $5.85
- Average True Range (ATR)
- MIRA 0.18
- SONN 0.55
- MACD
- MIRA 0.02
- SONN 0.08
- Stochastic Oscillator
- MIRA 35.00
- SONN 64.98
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.